These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25147919)

  • 1. RASA4 undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia.
    Poetsch AR; Lipka DB; Witte T; Claus R; Nöllke P; Zucknick M; Olk-Batz C; Fluhr S; Dworzak M; De Moerloose B; Starý J; Zecca M; Hasle H; Schmugge M; van den Heuvel-Eibrink MM; Locatelli F; Niemeyer CM; Flotho C; Plass C
    Epigenetics; 2014 Sep; 9(9):1252-60. PubMed ID: 25147919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
    Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
    Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia.
    Fluhr S; Boerries M; Busch H; Symeonidi A; Witte T; Lipka DB; Mücke O; Nöllke P; Krombholz CF; Niemeyer CM; Plass C; Flotho C
    Clin Epigenetics; 2016; 8():50. PubMed ID: 27158276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia.
    Wilhelm T; Lipka DB; Witte T; Wierzbinska JA; Fluhr S; Helf M; Mücke O; Claus R; Konermann C; Nöllke P; Niemeyer CM; Flotho C; Plass C
    Epigenetics; 2016; 11(2):110-9. PubMed ID: 26891149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome.
    Olk-Batz C; Poetsch AR; Nöllke P; Claus R; Zucknick M; Sandrock I; Witte T; Strahm B; Hasle H; Zecca M; Stary J; Bergstraesser E; De Moerloose B; Trebo M; van den Heuvel-Eibrink MM; Wojcik D; Locatelli F; Plass C; Niemeyer CM; Flotho C;
    Blood; 2011 May; 117(18):4871-80. PubMed ID: 21406719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Murakami N; Okuno Y; Yoshida K; Shiraishi Y; Nagae G; Suzuki K; Narita A; Sakaguchi H; Kawashima N; Wang X; Xu Y; Chiba K; Tanaka H; Hama A; Sanada M; Ito M; Hirayama M; Watanabe A; Ueno T; Kojima S; Aburatani H; Mano H; Miyano S; Ogawa S; Takahashi Y; Muramatsu H
    Blood; 2018 Apr; 131(14):1576-1586. PubMed ID: 29437595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Consensus Definition of DNA Methylation Subgroups in Juvenile Myelomonocytic Leukemia.
    Schönung M; Meyer J; Nöllke P; Olshen AB; Hartmann M; Murakami N; Wakamatsu M; Okuno Y; Plass C; Loh ML; Niemeyer CM; Muramatsu H; Flotho C; Stieglitz E; Lipka DB
    Clin Cancer Res; 2021 Jan; 27(1):158-168. PubMed ID: 33139265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient juvenile myelomonocytic leukemia in the setting of PTPN11 mutation and Noonan syndrome with secondary development of monosomy 7.
    O'Halloran K; Ritchey AK; Djokic M; Friehling E
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28084675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
    Niemeyer CM; Flotho C
    Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.
    Park HD; Lee SH; Sung KW; Koo HH; Jung NG; Cho B; Kim HK; Park IA; Lee KO; Ki CS; Kim SH; Yoo KH; Kim HJ
    Ann Hematol; 2012 Apr; 91(4):511-7. PubMed ID: 21901340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.
    Locatelli F; Algeri M; Merli P; Strocchio L
    Expert Rev Hematol; 2018 Feb; 11(2):129-143. PubMed ID: 29279013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia.
    Mulero-Navarro S; Sevilla A; Roman AC; Lee DF; D'Souza SL; Pardo S; Riess I; Su J; Cohen N; Schaniel C; Rodriguez NA; Baccarini A; Brown BD; Cavé H; Caye A; Strullu M; Yalcin S; Park CY; Dhandapany PS; Yongchao G; Edelmann L; Bahieg S; Raynal P; Flex E; Tartaglia M; Moore KA; Lemischka IR; Gelb BD
    Cell Rep; 2015 Oct; 13(3):504-515. PubMed ID: 26456833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
    Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
    Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical features and prognosis of juvenile myelomonocytic leukemia: an analysis of 63 cases].
    Yang WY; Liu LP; Liu F; Qi BQ; Chang LX; Zhang L; Chen XJ; Zou Y; Chen YM; Guo Y; Zhu XF
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Mar; 25(3):265-271. PubMed ID: 36946161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTPN11 mutation with additional somatic alteration indicates unfavorable outcome in juvenile myelomonocytic leukemia: a retrospective clinical study from a single center.
    Miao Y; Li B; Ding L; Zhu H; Luo C; Wang J; Luo C; Chen J
    Eur J Pediatr; 2020 Mar; 179(3):463-472. PubMed ID: 31807902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
    Gadgeel M; Bagla S; Buck S; Shamoun M; Ravindranath Y
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28555. PubMed ID: 32648963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
    Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
    Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Juvenile myelomonocytic leukemias].
    Lachenaud J; Strullu M; Baruchel A; Cavé H
    Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.